Phase 1b Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (ALK ) Gene Locus

Trial Profile

Phase 1b Open-Label Study Of The Safety And Clinical Activity Of Crizotinib (PF-02341066) In Tumors With Genetic Events Involving The Anaplastic Lymphoma Kinase (ALK ) Gene Locus

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 29 May 2018 According to the Pfizer media release, U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for XALKORI (crizotinib) for the treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma that is anaplastic lymphoma kinase (ALK)-positive, based on the results from this and other study (70047116).
    • 25 Jan 2018 Planned End Date changed from 29 Dec 2017 to 29 Dec 2018.
    • 25 Jan 2018 Planned primary completion date changed from 29 Dec 2017 to 29 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top